Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug LXE408 in people with chronic Chagas disease who do not have severe organ dysfunction. This phase 2, randomized, participant- and investigator-blinded study compares LXE408 to placebo and the standard treatment benznidazole. The goal is to assess the drugs ability to clear or reduce parasites in the blood, as well as its safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants are assigned to one of four groups LXE408 for 28 days, LXE408 for 14 days followed by placebo for 14 days, placebo for 28 days, or benznidazole for 60 days. The study involves oral administration of these treatments in a parallel group design. The treatment period is followed by monitoring to evaluate the effects and parasite clearance over time. During the study, participants undergo PCR testing at months 2, 4, 6, and 12 to check for sustained parasitological clearance. Other assessments include monitoring adverse events, blood drug levels at various days during treatment, and serology tests at months 6 and 12. The study also tracks participant health for up to 48 months to observe long-term outcomes and safety. Total participation may last several years including treatment and follow-up.